AZD1222 vaccine met primary efficacy endpoint in preventing COVID-19

Date:

Today marks an important step in turning the corner on the pandemic and getting things back to normal. Following the positive high-level results from an interim analysis of clinical trials of AZD1222 in the UK and Brazil, which showed the vaccine was highly effective in preventing COVID-19, we are confident that our united response, across the scientific community, industry, organisations, and governments, will make significant inroads in curbing the COVID-19 pandemic that has continued to claim thousands of lives every day in Africa and across the globe. We will continue to work hard to honour our commitment to make the vaccine available in a fair and equitable manner as rapidly as possible, following robust regulatory approval and meeting stringent efficacy and safety standards. It is a great day for innovation and for inclusion, an exciting moment for human health.

Barbara Nel Country President African Cluster: South Africa, Sub Saharan Africa, French Speaking Africa

Full AstraZeneca Regulatory News Service News Release available here (https://bit.ly/339VrKS).

 

SOURCE
AstraZeneca

Share post:

Subscribe

Popular

Finding solutions to everyday problems

Ghanaian developer’s free Gesture app lets users control a...

Tourism Ministry, GTA unveils December in GH 2026 events calendar .

The Ministry of Tourism and Ghana Tourism Authority (GTA)...

Ghana adopts national communiqué to strengthen climate and ESG Policies. 

– Ghana has adopted a National Communiqué outlining shared...

Scientists, partners converge at UHAS to concretize hold on innovation, resilience .

The Fourth Annual International Research Conference 2026 of the...

More like this
Related